Quest Diagnostics Lifts FY EPS View as Q2 Revenue Tops $3.04B
DGX sits 36% above its 52-week low of $165.777 on elevated volume (4.1× avg).
Summary
Quest Diagnostics posted Q2 2026 revenue of $3.04 billion (+10.2% YoY) and raised full-year adjusted EPS guidance to $11.05–$11.25, above consensus, driven by strong volume growth from new partnerships.
Key Events · Earnings and Guidance · DGX
-
Q2 Revenue and Earnings Beat
Revenue reached $3.04 billion, up 10.2% year-over-year, while adjusted EPS rose 19.1% to $3.12. Both metrics exceeded expectations.
-
Raised Full-Year Guidance
Management lifted FY adjusted EPS guidance to $11.05–$11.25, above the consensus estimate of $10.95, reflecting confidence in continued growth.
-
Volume Growth Driven by New Partnerships
Total volume increased 13.1%, with organic growth of 13.0%. Approximately 9% of organic growth came from new relationships with Corewell Health and Fresenius Medical Care.
-
Revenue per Requisition Pressure from Mix
Revenue per requisition declined 2.8% due to a higher proportion of routine tests from new partnerships. Excluding these, revenue per requisition rose approximately 3%.
Analysis · DGX · Industrial Applications And Services
A strong second quarter saw revenue climb 10.2% to $3.04 billion and adjusted EPS reach $3.12, handily beating expectations. Confidence in the trajectory prompted management to raise full-year adjusted EPS guidance to $11.05–$11.25, above the $10.95 consensus. Volume surged 13.1%, fueled by new partnerships with Corewell Health and Fresenius Medical Care, though revenue per requisition dipped on mix. The balance sheet remains robust following a $500 million debt refinancing and $100 million in share repurchases. With no control or legal concerns, the quarterly report underscores sustained momentum and a constructive outlook, making it highly relevant for investors.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DGX was trading at $225.14 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $165.78 to $237.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.